Amicus Therapeutics (FOLD) Financials

$6.67 -0.01 (-0.15%)

Closing price 05/2/2025 04:00 PM Eastern

Extended Trading

$6.63 -0.04 (-0.54%)

As of 05/2/2025 07:25 PM Eastern

Annual Income Statements for Amicus Therapeutics

This table shows Amicus Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-132	-200	-284	-356	-277	-250	-237	-152	-56
Consolidated Net Income / (Loss)	-132	-200	-284	-356	-277	-250	-237	-152	-56
Net Income / (Loss) Continuing Operations	-132	-200	-284	-356	-277	-250	-237	-152	-56
Total Pre-Tax Income	-132	-204	-449	-356	-274	-242	-242	-150	-29
Total Operating Income	-130	-182	-442	-304	-247	-206	-212	-77	25
Total Gross Profit	0.00	4.13	31	160	230	271	291	362	475
Total Revenue	0.00	4.96	37	182	261	306	329	399	528
Operating Revenue	-	4.96	37	182	261	306	329	399	528
Total Cost of Revenue	0.00	0.83	6.24	22	31	34	39	37	53
Operating Cost of Revenue	-	0.83	6.24	22	31	34	39	37	53
Total Operating Expenses	130	186	473	464	477	478	503	439	450
Selling, General & Admin Expense	47	71	89	170	156	193	213	275	323
Research & Development Expense	77	105	149	286	308	272	277	152	109
Depreciation Expense	1.83	3.24	3.59	4.78	8.85	6.21	5.34	7.87	8.55
Other Operating Expenses / (Income)	-	-	0.00	0.00	-	0.26	0.00	-	0.00
Impairment Charge	-	0.00	465	-	0.00	0.00	6.62	1.13	0.00
Restructuring Charge	0.02	0.07	-	-	-	-	0.00	0.00	9.19
Other Special Charges / (Income)	4.38	6.76	-234	3.30	3.14	6.51	1.08	2.58	0.00
Total Other Income / (Expense), net	-1.68	-22	-7.14	-52	-27	-35	-30	-73	-54
Interest Expense	1.58	5.40	17	19	22	32	37	64	50
Interest & Investment Income	0.93	1.60	4.10	10	3.23	0.51	3.02	7.08	5.41
Other Income / (Expense), net	-1.03	-18	6.01	-43	-8.06	-2.90	4.18	-16	-9.44
Income Tax Expense	-	-3.74	-165	0.48	2.60	8.91	-5.47	1.48	27
Basic Earnings per Share	($1.20)	($1.49)	($1.85)	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)
Weighted Average Basic Shares Outstanding	109.92M	134.40M	153.36M	240.42M	258.87M	271.42M	289.06M	295.16M	304.38M
Diluted Earnings per Share	($1.20)	($1.49)	($1.85)	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)
Weighted Average Diluted Shares Outstanding	109.92M	134.40M	153.36M	240.42M	258.87M	271.42M	289.06M	295.16M	304.38M
Weighted Average Basic & Diluted Shares Outstanding	109.92M	134.40M	153.36M	240.42M	258.87M	280.03M	282.71M	295.38M	300.12M

This table shows Amicus Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-33	-56	-53	-43	-22	-34	-48	-16	-6.73	15
Consolidated Net Income / (Loss)	-33	-56	-53	-43	-22	-34	-48	-16	-6.73	15
Net Income / (Loss) Continuing Operations	-33	-56	-53	-43	-22	-34	-48	-16	-6.73	15
Total Pre-Tax Income	-29	-70	-53	-41	-25	-32	-44	0.11	6.79	7.93
Total Operating Income	-34	-42	-38	-19	-17	-3.69	-28	15	22	16
Total Gross Profit	68	79	79	85	94	104	97	115	128	135
Total Revenue	82	88	86	95	104	115	110	127	142	150
Operating Revenue	82	88	86	95	104	115	110	127	142	150
Total Cost of Revenue	13	9.38	6.94	9.11	9.95	11	14	11	13	15
Operating Cost of Revenue	13	9.38	6.94	9.11	9.95	11	14	11	13	15
Total Operating Expenses	102	121	117	104	111	108	125	100	107	119
Selling, General & Admin Expense	47	54	74	65	66	70	88	74	75	87
Research & Development Expense	53	64	41	35	41	35	28	25	26	30
Depreciation Expense	1.29	1.31	1.26	2.21	2.23	2.18	2.15	2.18	2.17	2.04
Total Other Income / (Expense), net	4.58	-28	-16	-22	-7.68	-28	-16	-15	-15	-8.04
Interest Expense	9.62	11	12	12	13	27	12	13	13	12
Interest & Investment Income	0.56	1.97	2.20	1.74	1.47	1.67	1.54	1.37	1.08	1.42
Other Income / (Expense), net	14	-19	-6.19	-11	3.83	-2.63	-4.97	-3.72	-3.26	2.51
Income Tax Expense	4.02	-14	-0.29	2.72	-3.13	2.18	4.84	16	14	-6.81
Basic Earnings per Share	($0.12)	($0.19)	($0.18)	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05
Weighted Average Basic Shares Outstanding	289.22M	289.06M	291.34M	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M
Diluted Earnings per Share	($0.12)	($0.19)	($0.18)	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05
Weighted Average Diluted Shares Outstanding	289.22M	289.06M	291.34M	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M
Weighted Average Basic & Diluted Shares Outstanding	280.95M	282.71M	284.58M	287.12M	293.25M	295.38M	296.20M	296.59M	298.81M	300.12M

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	45	118	-136	30	64	20	83	-96	97	-33
Net Cash From Operating Activities	-100	-150	-214	-300	-250	-233	-202	-167	-69	-34
Net Cash From Continuing Operating Activities	-100	-150	-214	-300	-249	-233	-202	-167	-69	-34
Net Income / (Loss) Continuing Operations	-132	-200	-284	-349	-356	-277	-250	-237	-152	-56
Consolidated Net Income / (Loss)	-132	-200	-284	-349	-356	-277	-250	-237	-152	-56
Depreciation Expense	1.83	3.24	3.59	4.22	4.78	8.85	6.21	5.34	7.87	8.55
Amortization Expense	-	2.69	9.70	11	2.55	1.79	2.49	2.63	2.62	2.26
Non-Cash Adjustments To Reconcile Net Income	11	39	483	35	85	62	51	101	101	110
Changes in Operating Assets and Liabilities, net	19	4.81	-426	-1.43	15	-29	-12	-39	-29	-99
Net Cash From Investing Activities	-145	-4.51	-171	-121	95	-14	79	92	98	-0.56
Net Cash From Continuing Investing Activities	-145	-4.51	-171	-121	95	-14	79	92	98	-0.56
Purchase of Property, Plant & Equipment	-4.82	-5.95	-4.53	-6.31	-20	-3.23	-3.88	-3.77	-7.44	-3.55
Purchase of Investments	-290	-220	-490	-578	-384	-365	-341	-243	-92	-115
Sale of Property, Plant & Equipment	-	-	-	-	-	0.00	0.00	3.41	0.00	0.00
Sale and/or Maturity of Investments	290	221	324	464	499	355	424	336	197	118
Net Cash From Financing Activities	291	273	247	451	218	263	212	-7.46	62	5.12
Net Cash From Continuing Financing Activities	291	273	247	451	218	263	212	-7.46	62	5.12
Repayment of Debt	-15	-80	-0.31	0.00	0.00	-155	0.00	0.00	-408	0.00
Issuance of Debt	50	273	0.00	147	0.00	386	0.00	0.00	387	0.00
Issuance of Common Equity	243	97	243	295	189	0.00	0.00	0.00	63	20
Other Financing Activities, net	15	-15	6.30	12	32	32	212	-7.46	19	-14
Effect of Exchange Rate Changes	-	-	-	-	-	-	-5.05	-	-	-4.03
Cash Interest Paid	0.61	2.99	7.42	7.50	17	25	30	34	36	59
Cash Income Taxes Paid	-	-	-	1.06	0.69	10	20	1.61	8.53	8.21

This table details how cash moves in and out of Amicus Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	42	-128	12	49	52	-16	-37	-0.44	24	-20
Net Cash From Operating Activities	-12	-81	-18	-16	-38	3.46	-30	23	-23	-3.92
Net Cash From Continuing Operating Activities	-12	-81	-18	-16	-38	3.46	-30	23	-23	-3.92
Net Income / (Loss) Continuing Operations	-33	-56	-53	-43	-22	-34	-48	-16	-6.73	15
Consolidated Net Income / (Loss)	-33	-56	-53	-43	-22	-34	-48	-16	-6.73	15
Depreciation Expense	1.29	1.31	1.26	2.21	2.23	2.18	2.15	2.18	2.17	2.04
Amortization Expense	0.67	0.67	0.67	0.69	0.72	0.54	0.53	0.56	0.57	0.60
Non-Cash Adjustments To Reconcile Net Income	22	23	41	29	11	20	38	25	25	22
Changes in Operating Assets and Liabilities, net	-2.55	-50	-7.84	-4.52	-31	14	-22	11	-44	-44
Net Cash From Investing Activities	75	-67	36	50	36	-24	7.54	-22	34	-20
Net Cash From Continuing Investing Activities	75	-67	36	50	36	-24	7.54	-22	34	-20
Purchase of Property, Plant & Equipment	0.14	-2.68	-1.94	-2.20	-1.57	-1.73	-1.81	-1.10	-0.36	-0.29
Purchase of Investments	-1.48	-143	-17	-20	-17	-39	-30	-44	-4.91	-36
Sale and/or Maturity of Investments	76	76	55	72	54	16	39	23	40	16
Net Cash From Financing Activities	-0.56	0.56	-7.83	24	38	8.21	-13	-0.86	18	1.10
Net Cash From Continuing Financing Activities	-0.56	0.56	-7.83	24	38	8.21	-13	-0.86	18	1.10
Issuance of Common Equity	-	-	2.35	24	37	-	0.00	-	19	0.41
Other Financing Activities, net	-0.56	0.56	-10	-0.53	1.06	29	-13	-0.86	-0.96	0.68
Cash Interest Paid	8.95	10	11	12	12	0.64	12	12	24	11
Cash Income Taxes Paid	0.23	0.67	0.18	5.80	0.50	2.05	0.64	0.49	1.60	5.49

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	908	1,037	627	790	850	887	905	724	778	785
Total Current Assets	217	340	392	551	520	579	597	424	483	505
Cash & Equivalents	69	187	49	80	143	163	245	149	247	214
Short-Term Investments	145	143	310	424	310	320	237	145	39	36
Accounts Receivable	-	1.30	9.46	22	33	47	53	66	88	101
Inventories, net	0.00	3.42	4.62	8.39	14	20	27	24	60	119
Prepaid Expenses	2.57	4.99	19	17	20	30	35	40	50	35
Plant, Property, & Equipment, net	6.18	9.82	9.06	11	48	44	42	31	32	29
Total Noncurrent Assets	686	687	226	227	282	263	266	270	263	251
Goodwill	198	198	198	198	198	198	198	198	198	198
Intangible Assets	487	487	23	23	23	23	23	23	20	17
Other Noncurrent Operating Assets	1.11	2.47	5.20	6.68	62	42	45	49	45	36
Total Liabilities & Shareholders' Equity	908	1,037	627	790	850	887	905	724	778	785
Total Liabilities	561	677	274	447	374	600	598	601	618	591
Total Current Liabilities	74	111	70	86	129	130	146	139	168	149
Accounts Payable	32	41	54	81	22	17	22	15	15	13
Accrued Expenses	-	-	-	-	100	97	98	94	144	127
Other Current Liabilities	-	-	-	-	7.19	6.87	7.41	8.55	8.32	8.46
Total Noncurrent Liabilities	487	566	204	361	245	470	452	462	450	442
Long-Term Debt	-	154	164	322	150	389	389	392	388	390
Other Noncurrent Operating Liabilities	233	216	19	23	82	69	52	70	62	52
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	348	360	353	343	476	286	307	123	160	194
Total Preferred & Common Equity	348	360	353	343	476	286	307	123	160	194
Total Common Equity	348	360	353	343	476	286	307	123	160	194
Common Stock	919	1,122	1,402	1,742	2,230	2,311	2,598	2,668	2,839	2,929
Retained Earnings	-580	-780	-1,064	-1,412	-1,769	-2,045	-2,296	-2,532	-2,684	-2,740
Accumulated Other Comprehensive Income / (Loss)	-0.12	2.05	-2.10	0.07	2.83	8.23	4.98	-12	5.24	5.10
Other Equity Adjustments	8.76	16	16	13	12	12	0.08	0.08	0.07	0.07

This table presents Amicus Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	760	701	730	764	722	749	787
Total Current Assets	459	400	433	463	431	462	498
Cash & Equivalents	278	161	211	263	210	209	234
Short-Term Investments	77	107	54	17	30	51	16
Accounts Receivable	52	68	64	73	76	85	98
Inventories, net	13	27	51	57	61	81	115
Prepaid Expenses	38	37	52	53	54	35	35
Plant, Property, & Equipment, net	32	31	30	31	32	31	30
Total Noncurrent Assets	269	269	267	270	258	257	258
Goodwill	198	198	198	198	198	198	198
Intangible Assets	23	23	22	21	20	19	18
Other Noncurrent Operating Assets	48	49	47	51	41	40	42
Total Liabilities & Shareholders' Equity	760	701	730	764	722	749	787
Total Liabilities	627	598	619	631	591	617	608
Total Current Liabilities	165	138	159	169	142	168	158
Accounts Payable	12	25	14	23	9.21	32	13
Accrued Expenses	125	93	125	139	125	128	136
Other Current Liabilities	7.54	8.01	7.84	7.77	8.27	8.11	8.54
Total Noncurrent Liabilities	462	460	459	461	449	449	450
Long-Term Debt	391	393	393	394	388	389	389
Other Noncurrent Operating Liabilities	60	61	60	61	61	60	60
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	133	103	112	133	131	133	179
Total Preferred & Common Equity	133	103	112	133	131	133	179
Total Common Equity	133	103	112	133	131	133	179
Common Stock	2,648	2,695	2,736	2,790	2,856	2,872	2,909
Retained Earnings	-2,477	-2,585	-2,629	-2,650	-2,732	-2,748	-2,755
Accumulated Other Comprehensive Income / (Loss)	-39	-6.74	4.16	-6.77	6.64	8.79	25
Other Equity Adjustments	0.08	0.08	0.07	0.07	0.07	0.07	0.07

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-100.00%	0.00%	644.86%	0.00%	0.00%	43.16%	17.11%	7.76%	21.30%	32.29%
EBITDA Growth	-92.82%	-49.69%	-117.82%	23.83%	-5.59%	28.11%	17.91%	0.33%	58.69%	131.77%
EBIT Growth	-91.15%	-52.12%	-118.00%	22.67%	-3.01%	26.56%	17.93%	0.66%	55.23%	116.58%
NOPAT Growth	-89.86%	-39.45%	-143.00%	17.66%	7.52%	18.76%	16.42%	-2.75%	63.60%	132.22%
Net Income Growth	-91.68%	-51.41%	-41.97%	-22.88%	-2.12%	22.32%	9.53%	5.55%	35.92%	62.99%
EPS Growth	-29.03%	-24.17%	-24.16%	0.00%	0.00%	27.70%	14.02%	10.87%	37.80%	64.71%
Operating Cash Flow Growth	-93.81%	-49.94%	-42.32%	-40.37%	16.52%	6.84%	13.20%	17.74%	58.52%	50.95%
Free Cash Flow Firm Growth	-814.54%	55.72%	-56.33%	-8.64%	-0.77%	10.88%	12.24%	10.29%	53.85%	24.73%
Invested Capital Growth	764.81%	10.87%	-30.58%	-3.81%	7.91%	16.21%	15.83%	4.17%	7.81%	27.64%
Revenue Q/Q Growth	-100.00%	133.10%	47.53%	0.00%	0.00%	6.22%	3.94%	1.84%	7.25%	7.01%
EBITDA Q/Q Growth	-18.47%	-10.91%	-3.55%	-1.30%	-7.56%	8.05%	-0.23%	5.30%	40.13%	1,617.54%
EBIT Q/Q Growth	-18.39%	-12.43%	-3.87%	-1.44%	-6.55%	7.26%	0.29%	5.18%	36.98%	264.89%
NOPAT Q/Q Growth	-17.46%	-2.26%	-5.31%	-0.55%	-6.87%	8.92%	-3.67%	12.32%	33.35%	377.19%
Net Income Q/Q Growth	-20.12%	-8.55%	-3.86%	-2.61%	-3.38%	6.21%	-4.98%	10.38%	12.69%	46.41%
EPS Q/Q Growth	-11.11%	-3.47%	-1.09%	0.00%	6.92%	4.46%	-2.22%	10.87%	13.56%	47.06%
Operating Cash Flow Q/Q Growth	-26.54%	2.54%	-24.05%	3.96%	1.12%	3.32%	-11.38%	-6.56%	54.94%	-27.81%
Free Cash Flow Firm Q/Q Growth	-18.53%	19.98%	-17.64%	10.55%	-8.26%	2.57%	-6.89%	-18.97%	47.50%	19.06%
Invested Capital Q/Q Growth	19.04%	-2.36%	9.14%	-7.85%	-5.53%	0.75%	3.44%	28.49%	6.00%	4.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	83.20%	83.11%	0.00%	87.95%	88.10%	88.72%	88.28%	90.65%	89.98%
EBITDA Margin	0.00%	-3,913.96%	-1,144.55%	0.00%	-186.55%	-93.69%	-65.67%	-60.74%	-20.69%	4.97%
Operating Margin	0.00%	-3,668.62%	-1,196.82%	0.00%	-166.84%	-94.68%	-67.57%	-64.43%	-19.33%	4.71%
EBIT Margin	0.00%	-4,033.58%	-1,180.55%	0.00%	-190.57%	-97.76%	-68.52%	-63.16%	-23.31%	2.92%
Profit (Net Income) Margin	0.00%	-4,034.73%	-769.03%	0.00%	-195.56%	-106.12%	-81.98%	-71.85%	-37.96%	-10.62%
Tax Burden Percent	100.00%	98.17%	63.24%	99.97%	100.13%	100.95%	103.69%	97.74%	100.99%	195.11%
Interest Burden Percent	100.49%	101.90%	103.01%	103.54%	102.48%	107.53%	115.39%	116.40%	161.23%	-186.30%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-55.70%	-151.95%	0.00%	-127.56%	-92.35%	-66.53%	-62.39%	-21.42%	5.84%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	2.28%	-168.56%	0.00%	-68.44%	-38.81%	66.45%	-448.95%	-109.50%	-54.96%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-0.81%	72.29%	0.00%	40.56%	19.76%	-17.83%	-47.54%	-85.62%	-37.52%
Return on Equity (ROE)	-56.22%	-56.51%	-79.66%	-100.32%	-86.99%	-72.59%	-84.37%	-109.93%	-107.04%	-31.68%
Cash Return on Invested Capital (CROIC)	-157.16%	-66.01%	-115.85%	-136.72%	-135.16%	-107.34%	-81.20%	-66.48%	-28.94%	-18.44%
Operating Return on Assets (OROA)	0.00%	-20.56%	-52.41%	0.00%	-42.35%	-29.37%	-23.37%	-25.53%	-12.40%	1.98%
Return on Assets (ROA)	0.00%	-20.57%	-34.14%	0.00%	-43.46%	-31.88%	-27.96%	-29.04%	-20.18%	-7.18%
Return on Common Equity (ROCE)	-56.22%	-56.51%	-79.66%	-100.32%	-86.99%	-72.59%	-84.37%	-109.93%	-107.04%	-31.68%
Return on Equity Simple (ROE_SIMPLE)	-37.98%	-55.54%	-80.49%	-101.77%	-74.80%	-96.67%	-81.49%	-192.26%	-94.64%	-28.91%
Net Operating Profit after Tax (NOPAT)	-91	-127	-309	-230	-213	-173	-145	-148	-54	17
NOPAT Margin	0.00%	-2,568.03%	-837.77%	0.00%	-116.79%	-66.27%	-47.30%	-45.10%	-13.53%	3.30%
Net Nonoperating Expense Percent (NNEP)	-28.56%	-57.99%	16.61%	-64.52%	-59.12%	-53.54%	-132.98%	386.56%	88.08%	60.80%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-27.68%	-9.86%	2.98%
Cost of Revenue to Revenue	0.00%	16.80%	16.89%	0.00%	12.05%	11.90%	11.28%	11.72%	9.35%	10.02%
SG&A Expenses to Revenue	0.00%	1,435.07%	240.11%	0.00%	93.21%	59.95%	63.08%	64.71%	68.93%	61.21%
R&D to Revenue	0.00%	2,113.61%	404.31%	0.00%	157.15%	118.23%	89.05%	84.04%	38.16%	20.70%
Operating Expenses to Revenue	0.00%	3,751.82%	1,279.93%	0.00%	254.78%	182.78%	156.37%	152.70%	109.99%	85.27%
Earnings before Interest and Taxes (EBIT)	-131	-200	-436	-337	-347	-255	-209	-208	-93	15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-130	-194	-423	-322	-340	-244	-201	-200	-83	26
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.48	1.96	6.78	0.00	5.21	21.01	10.47	27.88	25.98	14.51
Price to Tangible Book Value (P/TBV)	0.00	0.00	18.12	0.00	9.71	91.75	37.17	0.00	0.00	0.00
Price to Revenue (P/Rev)	0.00	142.67	64.79	0.00	13.62	23.06	10.53	10.42	10.42	5.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	4.79	2.44	13.22	0.00	12.58	29.47	13.49	14.62	16.28	8.84
Enterprise Value to Revenue (EV/Rev)	0.00	118.51	59.75	0.00	11.95	22.74	10.29	10.78	10.67	5.59
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	112.59
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	191.44
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	169.69
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.12	0.58	0.49	0.94	0.31	1.39	1.33	3.36	2.42	2.01
Long-Term Debt to Equity	0.00	0.43	0.47	0.94	0.31	1.36	1.27	3.19	2.42	2.01
Financial Leverage	-0.61	-0.35	-0.43	-0.53	-0.59	-0.51	-0.27	0.11	0.78	0.68
Leverage Ratio	2.38	2.75	2.33	2.04	2.00	2.28	3.02	3.79	5.30	4.41
Compound Leverage Factor	2.39	2.80	2.40	2.11	2.05	2.45	3.48	4.41	8.55	-8.22
Debt to Total Capital	10.64%	36.89%	32.84%	48.41%	23.89%	58.16%	57.05%	77.06%	70.77%	66.78%
Short-Term Debt to Total Capital	10.64%	9.83%	1.60%	0.00%	0.00%	1.30%	2.64%	3.99%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	27.06%	31.25%	48.41%	23.89%	56.86%	54.41%	73.07%	70.77%	66.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	89.36%	63.11%	67.16%	51.59%	76.11%	41.84%	42.95%	22.94%	29.23%	33.22%
Debt to EBITDA	-0.32	-1.09	-0.41	-1.00	-0.44	-1.63	-2.03	-2.07	-4.70	14.86
Net Debt to EBITDA	1.33	0.62	0.44	0.57	0.89	0.35	0.37	-0.60	-1.23	5.34
Long-Term Debt to EBITDA	0.00	-0.80	-0.39	-1.00	-0.44	-1.59	-1.94	-1.96	-4.70	14.86
Debt to NOPAT	-0.45	-1.65	-0.56	-1.40	-0.70	-2.30	-2.83	-2.78	-7.18	22.40
Net Debt to NOPAT	1.89	0.94	0.60	0.79	1.42	0.49	0.51	-0.81	-1.88	8.05
Long-Term Debt to NOPAT	0.00	-1.21	-0.53	-1.40	-0.70	-2.25	-2.69	-2.64	-7.18	22.40
Altman Z-Score	0.11	-0.79	1.24	-3.20	0.49	2.74	-0.15	-1.49	-0.18	-0.75
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.94	3.06	5.60	6.40	4.04	4.47	4.09	3.05	2.88	3.39
Quick Ratio	2.91	2.99	5.25	6.11	3.77	4.09	3.67	2.59	2.23	2.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-341	-151	-236	-224	-226	-201	-176	-158	-73	-55
Operating Cash Flow to CapEx	-2,078.87%	-2,523.05%	-4,721.50%	-4,755.15%	-1,251.33%	-7,229.32%	-5,213.47%	-46,922.54%	-928.64%	-953.87%
Free Cash Flow to Firm to Interest Expense	-215.92	-27.95	-13.68	-9.99	-11.95	-8.96	-5.43	-4.26	-1.14	-1.11
Operating Cash Flow to Interest Expense	-63.46	-27.82	-12.40	-13.39	-13.27	-10.40	-6.24	-4.49	-1.08	-0.68
Operating Cash Flow Less CapEx to Interest Expense	-66.51	-28.92	-12.66	-13.67	-14.33	-10.55	-6.36	-4.50	-1.19	-0.75
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.01	0.04	0.00	0.22	0.30	0.34	0.40	0.53	0.68
Accounts Receivable Turnover	0.00	0.00	6.86	0.00	6.60	6.51	6.14	5.54	5.19	5.60
Inventory Turnover	0.00	0.00	1.55	0.00	1.96	1.85	1.49	1.52	0.89	0.59
Fixed Asset Turnover	0.00	0.62	3.91	0.00	6.17	5.70	7.08	8.99	12.79	17.31
Accounts Payable Turnover	0.00	0.02	0.13	0.00	0.43	1.60	1.79	2.09	2.45	3.77
Days Sales Outstanding (DSO)	0.00	0.00	53.21	0.00	55.33	56.11	59.49	65.89	70.30	65.20
Days Inventory Outstanding (DIO)	0.00	0.00	235.27	0.00	186.39	197.51	245.55	239.40	408.32	615.23
Days Payable Outstanding (DPO)	0.00	16,042.47	2,777.24	0.00	850.45	228.01	204.26	174.59	149.29	96.75
Cash Conversion Cycle (CCC)	0.00	-16,042.47	-2,488.76	0.00	-608.73	25.61	100.78	130.70	329.33	583.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	217	240	167	161	173	201	233	243	262	334
Invested Capital Turnover	0.00	0.02	0.18	0.00	1.09	1.39	1.41	1.38	1.58	1.77
Increase / (Decrease) in Invested Capital	249	24	-74	-6.36	13	28	32	9.73	19	72
Enterprise Value (EV)	1,039	588	2,207	-182	2,179	5,932	3,144	3,550	4,263	2,955
Market Capitalization	1,212	707	2,393	0.00	2,482	6,017	3,218	3,430	4,161	2,815
Book Value per Share	$2.78	$2.53	$2.12	$0.00	$1.87	$1.10	$1.10	$0.44	$0.55	$0.65
Tangible Book Value per Share	($2.70)	($2.28)	$0.79	$0.00	$1.00	$0.25	$0.31	($0.35)	($0.20)	($0.07)
Total Capital	389	571	525	665	626	685	716	536	548	584
Total Debt	41	211	173	322	150	398	408	413	388	390
Total Long-Term Debt	0.00	154	164	322	150	389	389	392	388	390
Net Debt	-173	-120	-186	-182	-303	-85	-74	120	102	140
Capital Expenditures (CapEx)	4.82	5.95	4.53	6.31	20	3.23	3.88	0.36	7.44	3.55
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-30	-45	-28	-39	-61	-25	-13	13	29	106
Debt-free Net Working Capital (DFNWC)	184	285	330	465	391	459	470	306	315	356
Net Working Capital (NWC)	143	229	322	465	391	450	451	285	315	356
Net Nonoperating Expense (NNE)	41	73	-25	119	144	104	106	88	98	74
Net Nonoperating Obligations (NNO)	-131	-120	-186	-182	-303	-85	-74	120	102	140
Total Depreciation and Amortization (D&A)	1.83	5.93	13	15	7.32	11	8.70	7.98	10	11
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	-910.55%	-76.46%	0.00%	-33.74%	-9.42%	-4.17%	3.83%	7.30%	20.08%
Debt-free Net Working Capital to Revenue	0.00%	5,752.44%	894.46%	0.00%	214.70%	175.82%	153.76%	93.01%	78.97%	67.39%
Net Working Capital to Revenue	0.00%	4,620.92%	871.72%	0.00%	214.70%	172.41%	147.57%	86.50%	78.97%	67.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.20)	($1.49)	($1.85)	$0.00	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)
Adjusted Weighted Average Basic Shares Outstanding	125.21M	194.82M	186.89M	0.00	257.24M	264.32M	271.42M	289.06M	295.16M	304.38M
Adjusted Diluted Earnings per Share	($1.20)	($1.49)	($1.85)	$0.00	($1.48)	($1.07)	($0.92)	($0.82)	($0.51)	($0.18)
Adjusted Weighted Average Diluted Shares Outstanding	125.21M	194.82M	186.89M	0.00	257.24M	264.32M	271.42M	289.06M	295.16M	304.38M
Adjusted Basic & Diluted Earnings per Share	($1.20)	($1.49)	($1.85)	($1.88)	($1.48)	($1.07)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	109.92M	134.40M	153.36M	185.79M	240.42M	258.87M	280.03M	282.71M	295.38M	300.12M
Normalized Net Operating Profit after Tax (NOPAT)	-88	-123	-148	-228	-211	-171	-140	-143	-51	24
Normalized NOPAT Margin	0.00%	-2,471.62%	-399.72%	0.00%	-115.52%	-65.43%	-45.81%	-43.46%	-12.88%	4.51%
Pre Tax Income Margin	0.00%	-4,110.15%	-1,216.14%	0.00%	-195.30%	-105.12%	-79.06%	-73.52%	-37.59%	-5.44%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-83.31	-37.05	-25.29	-15.05	-18.40	-11.37	-6.45	-5.60	-1.45	0.31
NOPAT to Interest Expense	-57.86	-23.59	-17.95	-10.27	-11.28	-7.71	-4.45	-4.00	-0.84	0.35
EBIT Less CapEx to Interest Expense	-86.37	-38.15	-25.55	-15.33	-19.46	-11.52	-6.57	-5.61	-1.57	0.24
NOPAT Less CapEx to Interest Expense	-60.91	-24.69	-18.21	-10.55	-12.34	-7.85	-4.57	-4.01	-0.96	0.28
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Amicus Therapeutics' official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	2.70%	7.23%	9.60%	17.06%	26.70%	30.63%	27.97%	34.04%	36.73%	30.09%
EBITDA Growth	54.36%	15.95%	41.31%	47.69%	43.89%	93.89%	28.40%	152.08%	306.43%	686.17%
EBIT Growth	52.08%	15.71%	40.32%	44.21%	34.72%	89.63%	25.41%	137.80%	239.47%	392.34%
NOPAT Growth	20.19%	41.33%	50.04%	68.88%	49.70%	91.28%	26.34%	-16,377.37%	-80.26%	1,248.02%
Net Income Growth	33.82%	32.92%	37.92%	30.45%	35.18%	39.42%	8.53%	63.69%	68.81%	143.55%
EPS Growth	36.84%	34.48%	40.00%	28.57%	41.67%	42.11%	11.11%	66.67%	71.43%	145.45%
Operating Cash Flow Growth	50.95%	-14.55%	69.01%	-1.71%	-229.84%	104.28%	-64.34%	240.65%	40.10%	-213.24%
Free Cash Flow Firm Growth	122.94%	52.22%	34.19%	-3,317.40%	-651.19%	45.23%	-90.06%	-3,065.39%	-33.08%	-98.12%
Invested Capital Growth	-16.14%	4.17%	1.79%	28.40%	30.68%	7.81%	16.07%	3.60%	28.97%	27.64%
Revenue Q/Q Growth	1.19%	7.84%	-2.07%	9.54%	9.52%	11.19%	-4.07%	14.73%	11.72%	5.79%
EBITDA Q/Q Growth	64.46%	-223.11%	28.95%	35.89%	61.88%	64.83%	-732.93%	146.64%	51.09%	-0.12%
EBIT Q/Q Growth	62.12%	-201.67%	28.10%	32.09%	55.68%	52.08%	-417.20%	134.42%	63.52%	0.43%
NOPAT Q/Q Growth	44.17%	-25.08%	11.08%	49.89%	9.74%	78.31%	-650.84%	-11,110.39%	99.01%	238.12%
Net Income Q/Q Growth	46.45%	-67.83%	5.25%	18.33%	50.09%	-56.85%	-43.07%	67.58%	57.13%	319.04%
EPS Q/Q Growth	42.86%	-58.33%	5.26%	16.67%	53.33%	-57.14%	-45.45%	68.75%	60.00%	350.00%
Operating Cash Flow Q/Q Growth	26.71%	-594.75%	77.63%	10.71%	-137.69%	109.02%	-958.73%	176.41%	-201.23%	82.95%
Free Cash Flow Firm Q/Q Growth	491.31%	-410.33%	22.33%	-125.76%	-1.30%	69.16%	-169.50%	-3,659.99%	95.74%	54.09%
Invested Capital Q/Q Growth	-3.81%	28.49%	-0.85%	4.78%	-2.10%	6.00%	6.74%	-6.47%	21.87%	4.91%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	83.55%	89.35%	91.95%	90.36%	90.39%	90.16%	87.71%	91.11%	90.62%	90.09%
EBITDA Margin	-22.34%	-66.94%	-48.57%	-28.43%	-9.89%	-3.13%	-27.18%	11.05%	14.94%	14.10%
Operating Margin	-41.42%	-48.05%	-43.63%	-19.96%	-16.45%	-3.21%	-25.11%	11.82%	15.30%	10.67%
EBIT Margin	-24.73%	-69.19%	-50.80%	-31.49%	-12.74%	-5.49%	-29.61%	8.88%	13.00%	12.34%
Profit (Net Income) Margin	-40.75%	-63.41%	-61.36%	-45.75%	-20.85%	-29.41%	-43.86%	-12.39%	-4.75%	9.85%
Tax Burden Percent	113.75%	79.72%	99.46%	106.70%	87.34%	106.90%	111.10%	-14,534.26%	-99.17%	185.77%
Interest Burden Percent	144.82%	114.97%	121.44%	136.14%	187.30%	500.95%	133.33%	0.96%	36.88%	42.94%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	14,634.26%	199.17%	-85.77%
Return on Invested Capital (ROIC)	-45.24%	-46.53%	-43.09%	-21.82%	-19.66%	-3.55%	-28.61%	-3,046.53%	-26.50%	35.13%
ROIC Less NNEP Spread (ROIC-NNEP)	-24.99%	-161.66%	-82.14%	-58.49%	-31.02%	-31.78%	-48.83%	-1,444.45%	-14.86%	22.78%
Return on Net Nonoperating Assets (RNNOA)	4.65%	-17.12%	-32.78%	-33.62%	-19.86%	-24.85%	-60.08%	-1,595.36%	-12.07%	15.55%
Return on Equity (ROE)	-40.59%	-63.64%	-75.87%	-55.44%	-39.53%	-28.41%	-88.69%	-4,641.89%	-38.57%	50.69%
Cash Return on Invested Capital (CROIC)	-64.18%	-66.48%	-52.92%	-66.25%	-63.80%	-28.94%	-32.98%	-12.66%	-24.01%	-18.44%
Operating Return on Assets (OROA)	-9.32%	-27.96%	-22.40%	-14.43%	-6.23%	-2.92%	-17.63%	5.47%	8.28%	8.34%
Return on Assets (ROA)	-15.35%	-25.63%	-27.06%	-20.95%	-10.19%	-15.64%	-26.12%	-7.63%	-3.03%	6.66%
Return on Common Equity (ROCE)	-40.59%	-63.64%	-75.87%	-55.44%	-39.53%	-28.41%	-88.69%	-4,641.89%	-38.57%	50.69%
Return on Equity Simple (ROE_SIMPLE)	-199.13%	0.00%	-199.12%	-166.08%	-130.30%	0.00%	-112.53%	-90.20%	-58.54%	0.00%
Net Operating Profit after Tax (NOPAT)	-24	-30	-26	-13	-12	-2.58	-19	-2,175	-21	30
NOPAT Margin	-29.00%	-33.63%	-30.54%	-13.97%	-11.51%	-2.25%	-17.58%	-1,717.34%	-15.18%	19.82%
Net Nonoperating Expense Percent (NNEP)	-20.25%	115.14%	39.05%	36.67%	11.35%	28.23%	20.22%	-1,602.08%	-11.64%	12.35%
Return On Investment Capital (ROIC_SIMPLE)	-	-5.52%	-	-	-	-0.47%	-	-	-	5.08%
Cost of Revenue to Revenue	16.45%	10.65%	8.05%	9.64%	9.61%	9.84%	12.29%	8.89%	9.38%	9.91%
SG&A Expenses to Revenue	57.87%	61.61%	85.73%	69.23%	63.43%	61.03%	79.73%	58.09%	53.07%	57.89%
R&D to Revenue	64.84%	72.50%	48.10%	37.19%	39.33%	30.44%	25.66%	19.49%	18.49%	20.17%
Operating Expenses to Revenue	124.98%	137.40%	135.29%	110.31%	106.84%	93.59%	112.82%	79.29%	75.31%	79.42%
Earnings before Interest and Taxes (EBIT)	-20	-61	-44	-30	-13	-6.32	-33	11	18	18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-18	-59	-42	-27	-10	-3.60	-30	14	21	21
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	22.09	27.88	30.57	32.03	26.20	25.98	26.43	22.17	17.71	14.51
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	9.06	10.42	9.31	10.20	9.38	10.42	8.16	6.45	6.42	5.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	15.79	14.62	13.59	14.72	14.60	16.28	12.89	11.73	10.38	8.84
Enterprise Value to Revenue (EV/Rev)	9.23	10.78	9.72	10.60	9.68	10.67	8.51	6.73	6.70	5.59
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,164.48	112.59
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	191.44
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	906.34	169.69
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.10	3.36	3.95	3.64	2.96	2.42	2.97	2.93	2.18	2.01
Long-Term Debt to Equity	2.95	3.19	3.83	3.53	2.96	2.42	2.97	2.93	2.18	2.01
Financial Leverage	-0.19	0.11	0.40	0.57	0.64	0.78	1.23	1.10	0.81	0.68
Leverage Ratio	3.37	3.79	4.48	5.37	5.73	5.30	6.10	6.06	4.97	4.41
Compound Leverage Factor	4.88	4.35	5.44	7.31	10.74	26.57	8.13	0.06	1.83	1.89
Debt to Total Capital	75.62%	77.06%	79.80%	78.46%	74.73%	70.77%	74.82%	74.59%	68.53%	66.78%
Short-Term Debt to Total Capital	3.65%	3.99%	2.49%	2.51%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	71.97%	73.07%	77.31%	75.95%	74.73%	70.77%	74.82%	74.59%	68.53%	66.78%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	24.38%	22.94%	20.20%	21.54%	25.27%	29.23%	25.18%	25.41%	31.47%	33.22%
Debt to EBITDA	-1.95	-2.07	-2.38	-2.78	-2.86	-4.70	-5.49	-13.03	254.90	14.86
Net Debt to EBITDA	-0.27	-0.60	-0.81	-0.96	-0.82	-1.23	-2.10	-4.32	91.45	5.34
Long-Term Debt to EBITDA	-1.85	-1.96	-2.30	-2.69	-2.86	-4.70	-5.49	-13.03	254.90	14.86
Debt to NOPAT	-2.43	-2.78	-3.32	-4.38	-4.86	-7.18	-8.24	-16.60	106.74	22.40
Net Debt to NOPAT	-0.33	-0.81	-1.13	-1.52	-1.40	-1.88	-3.16	-5.50	38.29	8.05
Long-Term Debt to NOPAT	-2.31	-2.64	-3.22	-4.24	-4.86	-7.18	-8.24	-16.60	106.74	22.40
Altman Z-Score	-0.96	-0.82	-1.30	-0.78	-0.64	0.18	-0.88	-1.15	-0.55	-0.73
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.78	3.05	2.89	2.72	2.73	2.88	3.03	2.75	3.15	3.39
Quick Ratio	2.47	2.59	2.42	2.07	2.09	2.23	2.22	2.05	2.20	2.36
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	13	-39	-31	-69	-70	-22	-58	-2,184	-93	-43
Operating Cash Flow to CapEx	0.00%	-3,017.26%	-930.43%	-732.65%	-2,450.29%	199.77%	-1,639.70%	2,066.58%	-6,452.53%	-1,359.72%
Free Cash Flow to Firm to Interest Expense	1.32	-3.55	-2.58	-5.52	-5.38	-0.81	-4.67	-174.59	-7.33	-3.57
Operating Cash Flow to Interest Expense	-1.21	-7.28	-1.53	-1.29	-2.95	0.13	-2.39	1.81	-1.81	-0.33
Operating Cash Flow Less CapEx to Interest Expense	-1.19	-7.52	-1.69	-1.47	-3.07	0.06	-2.53	1.73	-1.84	-0.35
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.38	0.40	0.44	0.46	0.49	0.53	0.60	0.62	0.64	0.68
Accounts Receivable Turnover	6.23	5.54	5.59	6.03	5.93	5.19	5.86	6.12	5.76	5.60
Inventory Turnover	2.10	1.52	1.48	1.08	1.01	0.89	1.00	0.69	0.57	0.59
Fixed Asset Turnover	8.69	8.99	10.21	10.97	11.72	12.79	13.27	14.84	16.05	17.31
Accounts Payable Turnover	2.03	2.09	1.59	2.12	2.01	2.45	2.57	2.02	2.70	3.77
Days Sales Outstanding (DSO)	58.56	65.89	65.35	60.53	61.57	70.30	62.32	59.63	63.36	65.20
Days Inventory Outstanding (DIO)	174.02	239.40	246.78	339.22	362.09	408.32	364.42	525.36	636.04	615.23
Days Payable Outstanding (DPO)	179.81	174.59	230.19	171.98	181.54	149.29	141.91	180.45	135.26	96.75
Cash Conversion Cycle (CCC)	52.77	130.70	81.93	227.77	242.12	329.33	284.84	404.55	564.15	583.68
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	189	243	241	252	247	262	279	261	319	334
Invested Capital Turnover	1.56	1.38	1.41	1.56	1.71	1.58	1.63	1.77	1.75	1.77
Increase / (Decrease) in Invested Capital	-36	9.73	4.22	56	58	19	39	9.09	72	72
Enterprise Value (EV)	2,985	3,550	3,274	3,715	3,605	4,263	3,603	3,067	3,307	2,955
Market Capitalization	2,928	3,430	3,135	3,574	3,491	4,161	3,454	2,938	3,168	2,815
Book Value per Share	$0.47	$0.44	$0.36	$0.39	$0.46	$0.55	$0.43	$0.45	$0.60	$0.65
Tangible Book Value per Share	($0.31)	($0.35)	($0.42)	($0.38)	($0.30)	($0.20)	($0.29)	($0.28)	($0.12)	($0.07)
Total Capital	544	536	508	518	527	548	519	521	568	584
Total Debt	411	413	405	406	394	388	388	389	389	390
Total Long-Term Debt	391	392	393	393	394	388	388	389	389	390
Net Debt	56	120	138	141	114	102	149	129	140	140
Capital Expenditures (CapEx)	-0.14	2.68	1.94	2.20	1.57	1.73	1.81	1.10	0.36	0.29
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-41	13	6.87	21	14	29	50	34	91	106
Debt-free Net Working Capital (DFNWC)	314	306	274	287	294	315	289	294	340	356
Net Working Capital (NWC)	294	285	261	274	294	315	289	294	340	356
Net Nonoperating Expense (NNE)	9.60	26	27	30	9.66	31	29	-2,160	-15	15
Net Nonoperating Obligations (NNO)	56	120	138	141	114	102	149	129	140	140
Total Depreciation and Amortization (D&A)	1.95	1.98	1.92	2.90	2.95	2.72	2.69	2.74	2.74	2.64
Debt-free, Cash-free Net Working Capital to Revenue	-12.68%	3.83%	2.04%	5.98%	3.63%	7.30%	11.70%	7.37%	18.35%	20.08%
Debt-free Net Working Capital to Revenue	97.04%	93.01%	81.35%	81.75%	78.90%	78.97%	68.28%	64.44%	68.94%	67.39%
Net Working Capital to Revenue	90.91%	86.50%	77.59%	78.04%	78.90%	78.97%	68.28%	64.44%	68.94%	67.39%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.12)	($0.19)	($0.18)	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05
Adjusted Weighted Average Basic Shares Outstanding	289.22M	289.06M	291.34M	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M
Adjusted Diluted Earnings per Share	($0.12)	($0.19)	($0.18)	($0.15)	($0.07)	($0.11)	($0.16)	($0.05)	($0.02)	$0.05
Adjusted Weighted Average Diluted Shares Outstanding	289.22M	289.06M	291.34M	292.80M	295.76M	295.16M	302.90M	303.77M	304.69M	304.38M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	280.95M	282.71M	284.58M	287.12M	293.25M	295.38M	296.20M	296.59M	298.81M	300.12M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-29	-26	-12	-11	-2.58	-15	10	17	11
Normalized NOPAT Margin	-28.51%	-32.37%	-30.54%	-12.88%	-10.16%	-2.25%	-13.74%	8.27%	12.27%	7.47%
Pre Tax Income Margin	-35.82%	-79.55%	-61.69%	-42.87%	-23.87%	-27.51%	-39.48%	0.09%	4.79%	5.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.10	-5.49	-3.70	-2.38	-1.02	-0.24	-2.63	0.90	1.45	1.55
NOPAT to Interest Expense	-2.46	-2.67	-2.22	-1.06	-0.92	-0.10	-1.56	-173.86	-1.69	2.48
EBIT Less CapEx to Interest Expense	-2.09	-5.74	-3.86	-2.56	-1.14	-0.30	-2.77	0.81	1.42	1.52
NOPAT Less CapEx to Interest Expense	-2.45	-2.91	-2.39	-1.23	-1.04	-0.16	-1.71	-173.95	-1.72	2.46
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Amicus Therapeutics' Financials

When does Amicus Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Amicus Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Amicus Therapeutics' net income changed over the last 8 years?

Amicus Therapeutics' net income appears to be on a downward trend, with a most recent value of -$56.11 million in 2024, falling from -$132.12 million in 2015. The previous period was -$151.58 million in 2023. See Amicus Therapeutics' forecast for analyst expectations on what’s next for the company.

What is Amicus Therapeutics's operating income?

Amicus Therapeutics's total operating income in 2024 was $24.88 million, based on the following breakdown:

Total Gross Profit: $475.35 million
Total Operating Expenses: $450.48 million

How has Amicus Therapeutics revenue changed over the last 8 years?

Over the last 8 years, Amicus Therapeutics' total revenue changed from $0.00 in 2015 to $528.30 million in 2024, a change of 52,829,500,000.0%.

How much debt does Amicus Therapeutics have?

Amicus Therapeutics' total liabilities were at $590.99 million at the end of 2024, a 4.3% decrease from 2023, and a 5.4% increase since 2015.

How much cash does Amicus Therapeutics have?

In the past 9 years, Amicus Therapeutics' cash and equivalents has ranged from $49.06 million in 2017 to $246.99 million in 2023, and is currently $213.75 million as of their latest financial filing in 2024.

How has Amicus Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Amicus Therapeutics' book value per share changed from 2.78 in 2015 to 0.65 in 2024, a change of -76.7%.

Related Companies

This page (NASDAQ:FOLD) was last updated on 5/5/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amicus Therapeutics (FOLD) Financials

Frequently Asked Questions About Amicus Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Amicus Therapeutics (FOLD) Financials

Annual Income Statements for Amicus Therapeutics

Quarterly Income Statements for Amicus Therapeutics

Annual Cash Flow Statements for Amicus Therapeutics

Quarterly Cash Flow Statements for Amicus Therapeutics

Annual Balance Sheets for Amicus Therapeutics

Quarterly Balance Sheets for Amicus Therapeutics

Annual Metrics and Ratios for Amicus Therapeutics

Quarterly Metrics and Ratios for Amicus Therapeutics

Frequently Asked Questions About Amicus Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools